Numerous neurotransmitters are involved in nociceptive transmission or regulation. Several reports have shown the analgesic effects of @entity1943 and its analogues. @entity1943 , when given intrathecally, markedly reduced @entity158 in @entity5 @entity1 . @entity1943 analogues that possess a longer half-life time are more convenient for therapeutic use. @entity35583 , a @entity1943 analogue, was shown to induce a long-lasting antinociceptive effect in @entity35 . We studied the site and the mechanism of action of @entity35583 in @entity35 using the paw pressure test. Intrathecal administration of @entity35583 induced no antinociception. Systemically administered @entity35583 -induced antinociception was inhibited by several intrathecal (i.t.) administered antagonists ( @entity3160 , @entity1510 and to a lesser degree tropisetron). These results show a lack of spinal effect and suggest a supraspinal site of action with an involvement of noradrenergic and to a lesser degree serotonergic bulbospinal pathways. In addition, spinal opioid receptors also seen to be involved.

Evidence for a role for bulbospinal pathways in the spinal antinociceptive effect of systemically administered XXXX in normal @entity35 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3160 :: ('MESH:D015016', 'Chemical') :: ['yohimbine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity35583 :: ('MESH:C051458', 'Chemical') :: ['Vapreotide', 'vapreotide'] @entity1510 :: ('MESH:D009270', 'Chemical') :: ['naloxone'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin', 'Somatostatin']
@entity35583 :: (MESH:C051458,Chemical) :: ['vapreotide']
